Primary brain cancer affects almost 2000 Australians every year and is sadly incurable.  

In this episode we’ll hear about how neuroscience might improve outcomes for people with brain cancer. 

Our guests are Professor Lucy Palmer, head of The Florey’s Neural Network Group. Lucy’s team works with live brain tissue samples donated by generous cancer patients, to better understand the relationship between tumours and the brain. 

We’ll also hear from Professor Kate Drummond, Director of Neurosurgery at The Royal Melbourne Hospital, who sees brain cancer every day and is acutely aware of what a research breakthrough would mean to patients and the community. 

And we’ll meet Janet Micaleff, a woman who has had reoccurring brain tumours for 40 years but somehow takes it all in her stride. Janet has become a voice for a community of people with similar lived experience.  

This is the final episode in Season 1.  We hope you’ve enjoyed listening, and we look forward to bringing you Season 2 later in the year. 

Send us a message

Support the show

What would you like our neuroscientists to talk about? Email us at [email protected]

We live in a world of plastic. Millions upon millions of tons are produced every year, meaning plastics are all around us - and it turns out – within us too. Around 16,000 chemicals are believed to involved in plastics in some form, and many of these chemicals make their way into our bodies.  

How do these human-made substances affect the brain?   

In this episode, we’ll hear about ways plastics are disrupting biological processes connected to brain function and development.  

Our guests are Florey neuro-epidemiologist, Professor Anne-Louise Ponsonby who is leading work to check the impact of plastics on children’s brains, and paediatrician Dr Christos Symeonides, an advocate with the Minderoo Foundation for stronger global regulation of plastic.  

Send us a message

Support the show

What would you like our neuroscientists to talk about? Email us at [email protected]

Motor neurone disease was first described in the 1800s, but it’s only in the last two decades that researchers have been able to make serious inroads into understanding this fatal neurodegenerative disease. 

Treatments remain very limited for patients and a cure is still some way off – but why is MND so challenging for patients, for their doctors and for researchers? Is there hope on the horizon?

In this episode, we tackle just that. Joining us is neurologist and Florey researcher, Dr Thanuja Dharmadasa, leader of The Florey’s MND research group, Professor Brad Turner, and Emma Vulin who was diagnosed with MND last year. 

Emma is a Member of the Victorian Parliament and, despite her diagnosis, she continues to serve her electorate and attend to her official duties while juggling medical appointments and life as a mother of two. 

Together with our host Dr Shane Huntington, our guests discuss the potential for personalised MND treatments and learn about world-first drug screening technology and MRI technology now in use at The Florey.

Send us a message

Support the show

What would you like our neuroscientists to talk about? Email us at [email protected]

Amber Starlight’s life as a teen was dictated by her seizures, sometimes happening several times a day. Her doctor knew something had to be done to gain seizure control – but with so many treatment routes to go down, it could be a long and challenging road ahead.    

Luckily for Amber, it was an unusual cause of her seizures that proved to be the key: brushing her teeth.  

The latest technology in imaging, particularly in magnetic resonance imaging (MRI), allows us to see the brain and its activity in an entirely new way. Researchers are finding new ways to push the boundaries of this technology every day.  

Amber’s experience of triggering a seizure during an advanced MRI scan enabled her doctors to take decisive action. And because they were able to see the precise location of the brain that they needed to treat, they were able to perform necessary surgery in a far less invasive way.  

In this episode, we speak to: patient Amber Starlight; neurologist Dr David Vaughan who is also a clinical researcher at The Florey and works on how MRIs can pinpoint sites for brain surgery; and physicist Associate Professor Heath Pardoe, head of neuroimaging at The Florey, who is interested in using neuroimaging to measure brain health. 

Send us a message

Support the show

What would you like our neuroscientists to talk about? Email us at [email protected]

Epilepsy is the most common neurological condition in the world affecting 50 million people. But the myriad of seizures types, seizure severity, clinical history, genetics and responses to medication can make it increasingly difficult to fully diagnose and treat. 

Add to this the variability in healthcare systems and infrastructure, the ‘postcode lottery’ of services available – particularly in rural and regional areas – and it’s no wonder that seizure control can feel out of reach for many. 

But does the digital era hold the key to improving outcomes for patients with epilepsy? What role can AI play in giving more people seizure control?

In this episode, we speak to Max Luca, aged 22, who has absence seizures – a type of epilepsy that causes brief lapses in consciousness. Even those closest to him struggled to figure out what it might be and if it was serious. 

Professor Graeme Jackson, Clinical Director from The Florey, joins us having spent decades treating epilepsy patients and more recently leading the Australian Epilepsy Project (AEP) – a digital research project turned healthcare model designed to expedite diagnosis and treatment for epilepsy. 

We are also joined by Professor Aileen McGonigal, Clinical Director of the Epilepsy Unit at Mater Hospital in Brisbane, Australia. Aileen has spent years in specialist clinical environments globally, including in the UK and France, and has signed her current unit up to the AEP. Aileen is also Max Luca’s doctor. 

Send us a message

Support the show

What would you like our neuroscientists to talk about? Email us at [email protected]

Multiple sclerosis, or MS, is a highly complex condition to diagnose, treat and live with. 

Affecting 1 in 1000 people, and with symptoms usually presenting in people between the age of 20 and 40, the impact of MS can vary person to person. Any part of the central nervous system can be impacted - from vision, to sensory perception and sometimes cognition. 

In this episode, we dive into the complexities of this disease with perspectives from leading MS clinician and researcher Professor Trevor Kilpatrick, Florey scientist Michele Binder, and Catherine, a doctor who has lived with MS for 20 years.  

The Brain Matters Podcast is brought to you by The Florey Institute of Neuroscience and Mental Health and hosted by Dr Shane Huntington. 

Send us a message

Support the show

What would you like our neuroscientists to talk about? Email us at [email protected]

An estimated 400 million people have an alcohol use disorder globally, with millions more experiencing problems with drugs and gambling. But, despite its magnitude, addiction is one of the most misunderstood health conditions. 

How does the human brain become addicted? Why are addictions so difficult to treat? And what does the future look like for people experiencing these neuropsychological problems?

Together with The Florey’s Professor Andy Lawrence, Turning Point’s Professor Dan Lubman and Lisa Rebecca, who has been in recovery for 12 years, we explore different perspectives on these complex questions.

Dan Lubman is a psychiatrist and addiction medicine specialist who is Executive Director of leading addiction treatment provider Turning Point. He talks us through the complexities of addiction in its many forms.

Andrew Lawrence is The Florey’s Deputy Director, and leads the institute's Addiction Neuroscience Group. He shares his insights into what drives addiction at the biological and cellular level and how that might help us find new treatments.

If this episode brings up any issues for you, contact:

• Turning Point for 24/7 advice and support on addiction via phone on 1800 250 015 or online at www.turningpoint.org.au (Australia)
• SMART Recovery, an evidence-based recovery method grounded in Cognitive Behavioural Therapy (CBT). Go to smartrecoveryaustralia.com.au

The Brain Matters Podcast is brought to you by The Florey Institute of Neuroscience and Mental Health and hosted by Dr Shane Huntington. 

Find out more about The Florey’s work at www.florey.edu.au 

Send us a message

Support the show

What would you like our neuroscientists to talk about? Email us at [email protected]

Globally, someone is diagnosed with dementia every 3 seconds. It’s a scary prospect for many of us as we age. But with blood tests for diagnosing dementia and promising medications on the horizon, does the future look brighter for this disease?

Annemarie's husband John started showing signs of dementia at just 58. She talks us through their journey of receiving an Alzheimer's diagnosis, and what it's like to live with this disease. 

Nawaf Yassi, a neurologist at the Royal Melbourne Hospital, talks us through the opportunities of new treatments and how the role of GPs will need to adapt in a new era for dementia.  

Rebecca Nisbet, a neuroscientist at The Florey working on innovative treatments for dementia, shares her excitement for new ways of getting medications into the brain to prevent the onset of dementia. 

Learn more about how you can support dementia research: www.florey.edu.au/more-time

Send us a message

Support the show

What would you like our neuroscientists to talk about? Email us at [email protected]